Loudonville, NY, United States of America

Igor B Roninson

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Senex Biotechnology, Inc., University of South Carolina. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Igor B Roninson. Retrieved from https://idiyas.com/inventor/igor-b-roninson-3692g4gc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Loudonville, NY (US) (2013)
Lexington, SC (US) (2013 - 2023)

Company Filing History:

9 out of 9

Senex Biotechnology, Inc.

patents

4 out of 706

University of South Carolina

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12281080 - Quinoline-based compounds and methods of inhibiting CDK8/19 (2025-04-21),

2. 11572369 - Bicyclic pyridine compositions and methods of using the same for cancer therapy (2023-02-07),

3. 11014906 - Quinoline-based compounds and methods of inhibiting CDK8/19 (2021-05-25),

4. 10993945 - CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer (2021-05-04),

5. 10584369 - Cell-based methods for measuring activity of a protein inhibitor (2020-03-10),

6. 9636342 - Method for treating prostate cancer (2017-05-02),

7. 9409873 - CDKI pathway inhibitors and uses thereof (2016-08-09),

8. 9321737 - CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer (2016-04-26),

9. 8598344 - CDKI pathway inhibitors and uses thereof (2013-12-03),

10. 8592147 - High-content screening for drugs against cancer and age-related diseases (2013-11-26),

Title: Igor B Roninson - Pioneering Cancer Therapies through Innovative Patents

Introduction:

Igor B Roninson, a distinguished inventor based in Loudonville, NY, has made significant contributions to the field of cancer therapy through his groundbreaking innovations. With a portfolio boasting nine patents, Roninson is a trailblazer in developing novel treatment methods for various diseases and conditions.

Latest Patents:

Among his latest patents is the development of bicyclic pyridine compositions for cancer therapy. These innovative compounds, including thienopyridine, pyrrolopyridine, and furopyridine derivatives, showcase Roninson's commitment to advancing cancer treatment modalities. Additionally, his work on quinoline-based compounds targeting CDK8 and CDK19 highlights his dedication to exploring new avenues for disease intervention.

Career Highlights:

Roninson's illustrious career includes significant stints at Senex Biotechnology, Inc. and the University of South Carolina. Through these roles, he has spearheaded groundbreaking research projects aimed at revolutionizing the field of oncology. His expertise and leadership have positioned him as a prominent figure in the biotechnology and academic spheres.

Collaborations:

Throughout his career, Roninson has collaborated closely with esteemed professionals in the industry, including Donald C Porter and Mark P Wentland. These collaborations have not only enriched his research endeavors but have also led to the development of cutting-edge therapeutic solutions that have the potential to transform patient care.

Conclusion:

In conclusion, Igor B Roninson's relentless pursuit of innovation in the realm of cancer therapy has solidified his reputation as a pioneering inventor. His patents stand as a testament to his unwavering commitment to advancing medical science and improving patient outcomes. As he continues to push the boundaries of what is possible in the field of biotechnology, the impact of his work is sure to resonate for years to come.

Profile summary based on public USPTO records.